https://www.coultreon.com/ 1 https://www.coultreon.com/team 0.8 https://www.coultreon.com/jobs 0.8 https://www.coultreon.com/news 0.9 https://www.coultreon.com/contact 0.7 https://www.coultreon.com/team/pierre-raboisson 0.6 https://www.coultreon.com/team/marie-de-vulder 0.6 https://www.coultreon.com/team/guy-peeters 0.6 https://www.coultreon.com/team/john-paul-gallivan 0.6 https://www.coultreon.com/team/lieve-lammens 0.6 https://www.coultreon.com/team/tom-govaerts 0.6 https://www.coultreon.com/team/gert-de-beckker 0.6 https://www.coultreon.com/team/fabrice-kolb 0.6 https://www.coultreon.com/team/pieter-peeters 0.6 https://www.coultreon.com/team/francois-gonzalvez 0.6 https://www.coultreon.com/team/sandrine-vendeville 0.6 https://www.coultreon.com/team/joost-kolkman 0.6 https://www.coultreon.com/team/lawrence-blatt 0.6 https://www.coultreon.com/team/rogier-rooswinkel 0.6 https://www.coultreon.com/team/maha-katabi 0.6 https://www.coultreon.com/team/max-klement 0.6 https://www.coultreon.com/news/approval-first-cta-sik-inhibitor-o3r-5671 2025-09-04 0.7 https://www.coultreon.com/news/onco3r-phase1-first-cohort-sik3-o3r-5671 2025-10-06 0.7 https://www.coultreon.com/news/onco3r-preclinical-portfolio-aacr-2025 2025-10-22 0.7 https://www.coultreon.com/news/completion-first-mad-cohort-phase-1-o3r-5671 2025-12-03 0.7 https://www.coultreon.com/news/lawrence-blatt-board-chair-appointment 2026-01-08 0.7 https://www.coultreon.com/news/o3r-5671-data-presentation-ecco-dosing-final-cohort 2026-01-09 0.7 https://www.coultreon.com/news/ecco-poster-presentation-o3r-5671-data 2026-02-20 0.7 https://www.coultreon.com/news/coultreon-biopharma-raises-125-million-series-a 2026-04-28 0.7 https://www.coultreon.com/presentations/the-first-in-class-sik3-inhibitor-o3r-5671-demonstrates-optimal-pharmacokinetics-and-potent-and-sustained-pharmacodynamic-activity-in-human-participants 2026-02-20T07:54:57.788Z 0.7 https://www.coultreon.com/presentations/discovery-of-a-novel-selective-sik3-inhibitor 2026-01-07T02:40:07.880Z 0.7